<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202540</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-18986-009</org_study_id>
    <nct_id>NCT00202540</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients</brief_title>
  <official_title>Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on
      episodic memory performance in patients with MCI
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 29, 2006</completion_date>
  <primary_completion_date type="Actual">March 29, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodic memory</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other cognitive domains, activities of daily living, global impression of change, MRI, safety.</measure>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S18986</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Memory complaint

          -  Acetylcholinesterase inhibitors stopped at least 3 months before selection

        Exclusion Criteria:

          -  Dementia

          -  Parkinson's disease

          -  Vascular disorder

          -  Depression

          -  Epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Vellas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital la Grave-Casselardit, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital la Grave-Casselardit</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.servier.com/wp-content/uploads/CL2-18986-009_synopsis_report.pdf</url>
    <description>Results summary</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

